The antiobese effect of AT1 receptor blockade is augmented in mice lacking Mas
- 25 Downloads
We recently showed that the antiobese efficacy of the AT1 receptor blocker telmisartan (TEL) is at least partially related to an Ang(1-7)-dependent mechanism. Ang(1-7) acts via Mas, thus raising the question of whether Mas-deficient (Mas-ko) mice are likewise predisposed to develop diet-induced obesity and, further, whether this can be prevented by TEL treatment. Mas-ko mice and FVB/N wild-type (wt) animals were treated with TEL (8 mg/kg/day) or vehicle while they were fed with high-fat diet (HFD) or chow. Mice were phenotyped regarding body weight, fat mass, insulin sensitivity, and leptin sensitivity. In response to HFD feeding, gain in body weight and impairment of leptin sensitivity were similar between wt and Mas-ko mice. TEL reduced body weight in both strains but effects were stronger in Mas-ko mice. TEL diminished fat mass and restored leptin sensitivity only in Mas-ko mice. Blood glucose was higher in wt than Mas-ko mice fed with HFD while not differing when they were fed with chow. Insulin challenge confirmed that wt mice became insulin resistant when fed with HFD while HFD feeding did not impair insulin sensitivity in Mas-ko mice. TEL had no further effect. Our findings on the influence of TEL on growth and metabolism in Mas-ko mice conflict with our previous findings in rats. We assume that the FVB/N background of the mice may partly explain these inconsistent data. Moreover, it also seems feasible that the MrgD receptor compensates for Mas deficiency.
KeywordsAngiotensins Antiobese Mas-ko mice
We thank Prof. Marcus Altfeld and Urte Matschl from the Heinrich Pette Institute, Hamburg, for the measurements with the luminex system. The authors gratefully acknowledge Sherryl Sundell for improving the English style.
CD, FS, IS, FV, NA, and LACS performed the research; WR, MB, and CD designed the research study; CD, FS, FV, NA, LACS, and WR analyzed the data; WR, MB, and CD wrote the paper.
Carla Dapper and Franziska Schuster were supported by a grant of the German Research Foundation to the Graduiertenkolleg 1957 “Adipocyte-Brain Crosstalk,” University of Lübeck. The study was supported by a grant of the German Centre for Cardiovascular Research (DZHK). Walter Raasch received Telmisartan from Boehringer Ingelheim Pharmaceuticals, Inc. (Ingelheim, Germany).
Compliance with ethical standards
All animal care and experimental procedures were in accordance with the NIH guidelines for the care and use of laboratory animals and were approved by the animal ethics committee of the local regulatory authority (Ministerium für Energiewende, Landwirtschaft, Umwelt, Natur und Digitalisierungdes Bundeslandes Schleswig-Holstein).
Conflict of interest
The authors declare that they have no conflicts of interest.
- Bharadwaj MS et al (2011) Angiotensin-converting enzyme 2 deficiency is associated with impaired gestational weight gain and fetal growth restriction. Hypertension 58:852–858. https://doi.org/10.1161/hypertensionaha.111.179358 CrossRefGoogle Scholar
- Choi MS, Kim YJ, Kwon EY, Ryoo JY, Kim SR, Jung UJ (2015) High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling- and inflammation-related genes. Br J Nutr 113:867–877. https://doi.org/10.1017/s0007114515000100 CrossRefGoogle Scholar
- Colombo C, Haluzik M, Cutson JJ, Dietz KR, Marcus-Samuels B, Vinson C, Gavrilova O, Reitman ML (2003) Opposite effects of background genotype on muscle and liver insulin sensitivity of lipoatrophic mice. Role of triglyceride clearance. J Biol Chem 278:3992–3999. https://doi.org/10.1074/jbc.M207665200 CrossRefGoogle Scholar
- Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, et al (2015) Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172:3461–3471Google Scholar
- Gustaityte V, Winkler M, Stoelting I, Raasch W (2018) Influence of AT1 blockers on obesity and stress induced eating of cafeteria diet. J Endocrinol. https://doi.org/10.1530/joe-18-0477
- He H et al (2010) Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. Hypertension 55:869–879. https://doi.org/10.1161/hypertensionaha.109.143958 CrossRefGoogle Scholar
- Hrenak J, Paulis L, Simko F (2016) Angiotensin A/Alamandine/MrgD Axis: another clue to understanding cardiovascular pathophysiology. Int J Mol Sci 17. https://doi.org/10.3390/ijms17071098
- Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T (2007) Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the treat to target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 6:12CrossRefGoogle Scholar
- Li H, Li M, Liu P, Wang YP, Zhang H, Li HB, Yang SF, Song Y, Yin YR, Gao L, Cheng S, Cai J, Tian G (2016) Telmisartan ameliorates nephropathy in metabolic syndrome by reducing leptin release from perirenal adipose tissue. Hypertension 68:478–490. https://doi.org/10.1161/hypertensionaha.116.07008 CrossRefGoogle Scholar
- Miesel A, Muller-Fielitz H, Johren O, Vogt FM, Raasch W (2012) Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats. Br J Pharmacol 165:2721–2735. https://doi.org/10.1111/j.1476-5381.2011.01726.x CrossRefGoogle Scholar
- Muller-Fielitz H, Markert A, Wittmershaus C, Pahlke F, Johren O, Raasch W (2011) Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. Naunyn Schmiedeberg's Arch Pharmacol 383:373–384CrossRefGoogle Scholar
- Muller-Fielitz H, Landolt J, Heidbreder M, Werth S, Vogt FM, Johren O, Raasch W (2012a) Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARgamma target gene regulation. Endocrinology 153:1103–1115. https://doi.org/10.1210/en.2011-0183 CrossRefGoogle Scholar
- Neubauer B, Schrankl J, Steppan D, Neubauer K, Sequeira-Lopez ML, Pan L, Gomez RA, Coffman TM, Gross KW, Kurtz A, Wagner C (2018) Angiotensin II short-loop feedback: is there a role of Ang II for the regulation of the renin system in vivo? Hypertension 71:1075–1082. https://doi.org/10.1161/hypertensionaha.117.10357 CrossRefGoogle Scholar
- Oliveira AC et al (2018) Genetic deletion of the alamandine receptor MRGD leads to dilated cardiomyopathy in mice. Am J Phys Heart Circ Phys. https://doi.org/10.1152/ajpheart.00075.2018
- Rong X et al (2010) Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. DiabetologiaGoogle Scholar
- Santos RA, Ferreira AJ, Verano-Braga T, Bader M (2012) Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin angiotensin system. J EndocrinolGoogle Scholar
- Santos SH et al (2013) Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats. J Mol Med (Berl)Google Scholar
- Silva AR et al (2013) Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. Am J Phys Regul Integr Comp Phys 305:R1323–R1330Google Scholar
- Trajcevski KE, O’Neill HM, Wang DC, Thomas MM, al-Sajee D, Steinberg GR, Ceddia RB, Hawke TJ (2013) Enhanced lipid oxidation and maintenance of muscle insulin sensitivity despite glucose intolerance in a diet-induced obesity mouse model. PLoS One 8:e71747. https://doi.org/10.1371/journal.pone.0071747 CrossRefGoogle Scholar
- Xu P et al (2008) Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 51:574–580. https://doi.org/10.1161/hypertensionaha.107.102764 CrossRefGoogle Scholar